

Keyword Index for Volume 109

- 1,25(OH)₂D₃ 723
¹³¹I-MIBG 565
¹⁸F-FDG-PET/CT 1157, 2973
5-azacytidine 1775
5-fluorouracil 1904, 2175, 2396
- abiraterone 1079
abiraterone acetate 325
ABO blood group 2462
ABVD chemotherapy 2560
ACE-inhibitors 249
acetylation 2675
acquired resistance 1876
actinomycin D 2954
acute lymphoblastic leukaemia 2189
acute promyelocytic leukaemia 2819
ADAM17 2217
ADCs 1570
adenoid cystic carcinoma 1117
adherence 1172, 1513
adiponectin 872
ADIPOQ 872
ADIPOR1 872
adiposity 751
adjuvant chemotherapy 545
adoptive T-cell therapy 658
advanced gastric cancer 2079
advanced hepatocellular cancer 888
advanced melanoma 1451
advanced NSCLC 1467
aerosol delivery 1775
aflibercept 1735
AFP routine test 1657
African American 1945
age 780, 1717, 2941
ageing 219
age-period 1310
AGO2 3116
AKT 1198, 1586
alcohol 859, 1945
ALDH1 109
ALK expression 2735
ALK gene amplification 2735
ALK mutation 2735
allogeneic haematopoietic stem cell transplantation 2523
anaplastic astrocytoma 844
anaplastic lymphoma kinase 3084
androgen 1279
androgen receptor 950, 1271
angiogenesis 360, 1230, 1243, 2072, 2597, 2842
angiogenesis inhibitor 538
angiopoietin-2 2072
animal models 1579
anti-androgen 983
anti-angiogenic 1725
anticancer therapy 1056
anti-platelet therapy 1921
- antisense oligonucleotide 2579
anti-tumour immunity 2167
AP-1 2248
apoptosis 164, 342, 433, 2189, 2434, 2685, 2696, 2792, 2853, 3034
aprepitant 859
AQUA 1859
aromatase 100
aromatase inhibitor 589, 1522, 2331
aromatase inhibitor resistance 1537
arsenic 235
asbestos 1965
ASNS 14
aspirin 249
attendance 597
AURKA 2445
Aurora kinases 2607
autophagy 164, 1040, 2434, 2597
- Bacillus Calmette-Guérin 2106
basal-like breast carcinoma 444
baseline sum longest diameter 1476
bcg 1460
BCG immunotherapy 2106
BerEP4 2217
bevacizumab 552, 1408, 1725
bexarotene 2566
biliary adenocarcinomas 915
biliary tract cancer 2665
biochemical recurrence 641
bioconductor and R packages 1394
biological interaction 2005
biomarkers 1, 147, 379, 395, 482, 530, 641, 694, 1013, 1562, 1782, 2096, 2228, 2356, 2445, 2765, 2864
birth cohort 2467
bispecific antibodies 934
bisphosphonates 795
bladder cancer 50, 121, 1040, 1460, 1586, 2106
blood biomarkers 1657
BLT2 351
BMP 1805
BMPRIA 1805
BMSC 1198
body mass index 289, 589, 751, 1522, 1899, 2894
boiled coffee 1344
bone markers 121
bone marrow 1264
bone marrow-derived cells 360
bone metastasis 3014
borderline ovarian tumours 2774
bowel 1504
BRAF 559
BRAF mutation 2833
BRCA mutation carriers 777
BRCA1 2347, 2724
BRCA2 2724
- breaking bad news 2507
breast biopsy 242
breast cancer, 42, 100, 109, 154, 257, 351, 582, 589, 597, 866, 872, 1157, 1172, 1291, 1302, 1310, 1513, 1522, 1528, 1543, 1556, 1676, 1693, 1829, 1876, 1886, 1926, 1945, 2035, 2175, 2331, 2472, 2783, 2792, 2798, 2965, 3034
breast cancer incidence 1296
breast cancer screening 242, 597
breast cancer therapy 1147
breast density 2331
breast neoplasms 1165
breast reconstruction 1181
buccodental toxicities 1750
Burkitt's lymphoma 280
- C35 965
C609T 1325
c-ABL 1100
CAF 926
caffeine 1908
CAIX 1859
cancer anorexia-cachexia 1867
cancer cell migration 1829
cancer chemoprevention 1
cancer genetics 497
cancer genome analysis 827
cancer incidence 1989
cancer inflammation 739
cancer prevalence 219
cancer registration 2875
cancer stem cell 379, 950, 1252, 2619
cancer survival 42
cancer survivors 891
cancer treatment 1549
cancer-associated fibroblasts 3049
cancer-specific survival 1899
capecitabine 1408, 1744
carboplatin 538, 859, 1072, 1467
carcinogenesis 3057
cardiovascular damage 891
cardiovascular disease 60
care closer to home 1549
case-control studies 795, 1360, 2472, 2904
castration-resistant prostate cancer 325, 1079, 1711, 2579
Caucasian 1821
CCL19 1100
CCR7 1100
CD4 helper T lymphocytes 2155
CD44 variant 9 379
CD8 2705
CDH-1 994
CDH-2 994
CDK 2356
Cdk inhibition 2378
- CDK6 2751
CDKN2A 2207
CEA 934
cediranib 943, 2765
celebrity 1192
cell cycle 3042
cell death biomarkers 2560
cell invasion 2810
cell membrane 195
cells of origin 1599
cellular motility 422
central tumour 184
cerebellum 844
cerebral cortex 844
cervical cancer 35, 92, 615, 1192, 1504, 2778
cervical cancer screening 1766
cetuximab 1117
changing presentation 2115
checkpoint receptors 2629
chemokine 1100, 2412
chemokines and chemokine receptors 1579, 2424
chemoprotection 2954
chemoprevention 249
chemoradiotherapy 1467
chemo-resistance 92, 965
chemotherapeutic 2131
chemotherapy 552, 891, 1117, 1243, 1414, 1428, 1549, 1904, 2175, 2340, 2554, 2954, 2980
chemotherapy response 370
Chernobyl 2286
childhood cancer 1373, 2880
childhood leukaemia 2880
children 844, 2515, 3084
chimeric antigen receptors 658
chloroquine 2597
choice 1181
cholangiocarcinoma 915, 2665, 3092
chondrosarcoma 1214
chordoma 2574
chromaffin cell tumour 565
chromogranin A 1414
chromosomal translocation 299
chromosome 16q 512
chromosome 1q 512
chromosome 6p 512
chronic 1504
chronic liver disease 1344, 1997
chronic lymphocytic leukaemia 1287
chronic myeloid leukaemia 1593
circulating microRNA 641
circulating tumour cells 1223, 2829
cisplatin 891, 915, 1904, 2096, 2548, 2980
cJun 3116
classification 1599, 1886
clear cell carcinoma 1899

- clinical decision support systems 1147
 clinical practice guidelines 1147
 clinical trial costs 2051
 clinical trials 897
 clinicopathologic 1302
 CLL 2434
 c-met 1271
 c-Met inhibitor 2619, 2803
 CNS tumour risk 289
 coffee 1352, 1908
 coffee preparation 1344
 cohort study 265, 761, 2496, 2886, 2917, 2924, 2933
 cohort study timing 1310
 cola 1908
 collagen Type XI α 1 3049
 colon cancer 138, 395, 994, 1023, 2175
 colonoscopy 1437
 colorectal cancer 24, 114, 131, 138, 307, 408, 667, 694, 807, 814, 934, 1004, 1013, 1338, 1352, 1408, 1420, 1437, 1618, 1636, 1725, 1744, 1782, 1839, 2207, 2445, 249, 2735, 2765
 colorectal liver metastases 2396
 colorectal neoplasms 387, 1243, 2005
 colposcopy 1766
 combination of platelet count and neutrophil to lymphocyte ratio 401
 combination study 943
 combination therapy 1085
 communication 836
 communication skills 2507
 community 1549
 comorbidity 265, 2489
 competing risks 1974
 compliance 1513
 computed tomography 1445
 computer-assisted image analysis 1839
 Concholepas haemocyanin 1488
 concordance 2875
 conjunctiva 1981
 consequences of cancer treatment 2121
 cooperation 1056
 copy number changes 2347
 cost attribution 2051
 cost-effectiveness 1172, 2295, 2533
 Coxsackievirus and Adenovirus receptor 1848
 CpG island methylator phenotype 1004
 CRC 694
 C-reactive protein 2066, 2316
 CrkL 1100
 CSCs 1876
 CT26 tumour 2167
 CTL 462
 curative treatment 272, 1609
 cutaneous T-cell lymphoma 2566
 cyclophosphamide 1725
 cyclotherapy 2954
 CYP2C19 polymorphism 2803
 cytokine 2072
 cytology 603, 1192
 cytotoxic T lymphocytes 462, 2705
 dacarbazine 1451
 DBC1 2675, 3042
 DCIS 100
 decaffeinated coffee 1908
 decision making 780, 2295
 deep remission 2998
 deleterious BRCA1/2 mutation 1072
 dendritic cells 462, 1488
 Denmark 2489
 dental hygiene 1367
 dermatology 497
 detection method 2833
 development 1
 diabetes mellitus type II 2924
 diagnosis 694, 807, 2027
 diagnostic tool 2646
 diagnostic workup 242
 diastolic heart function 891
 DICER1 2744
 diet 257, 1914, 2904
 diethylstilboestrol 1079
 differential expression 1848
 diffuse large B-cell lymphoma 312
 diffusion-weighted MRI 615, 1562
 disease progression 121
 disease-specific survival 1093
 disparities 1302
 disseminated tumour cells 1264
 disulfiram 1876
 DNA damage 2378, 3023
 DNA damage repair 68, 3042
 DNA damage response 1063
 DNA methylation, 530, 1394, 3073
 DNA repair proteins 68
 DNA-PKcs 2654
 Δ Np73 965
 docetaxel 1085
 donor lymphocyte infusion 2523
 dose escalation 651
 dose-response meta-analysis 1926
 dovitinib 2309
 doxorubicin 1206
 DPEP1 694
 DPYD 2347
 DR5 2685
 drug delivery 2142, 2368
 drug resistance 2607
 drug sensitivity 1063, 1599
 drug therapy 60
 DTH 1488
 DUSP6 1063
 dynamin 1 1867
 E6*I mRNA 172
 early breast cancer 2453
 early detection 603, 1437, 2489
 early detection lung cancer 530
 early recurrence 1648
 E-cadherin 2248
 ecological study 235
 EGFR 482, 1063
 EGFR inhibitors 1063
 EGFR mutation 1821
 elderly 852, 1717, 1744
 electronic patient-reported outcome monitoring 2301
 emergency 2027
 emotion 836
 EMT 307, 1666, 2248, 2587
 endocrine therapy 589, 1537, 2959
 endometrial cancer 215, 704, 756, 761, 1498, 1504, 1699, 1703, 1760, 1908, 1914
 endoplasmic reticulum stress 433, 3034
 EndoPredict 2959
 endoscopic procedure 379
 endovaginal 615
 England 235, 2058
 enteritis 1504
 environmental exposure 2886
 environmental radiation 2880
 EpCAM 2217
 EPHA2 2142
 EpiCD 2217
 epidemiology 257, 289, 756, 769, 795, 1287, 1318, 2005, 2880
 epidermal growth factor 207
 epidermal growth factor receptor 1821, 2155
 epidermal growth factor-like domain 7 1243
 epigenetic 2266
 epigenetic alteration 807
 epigenetics 408
 epigenome 1775
 epithelial ovarian cancer 1685
 epithelial-to-mesenchymal transition 184, 307
 ERCC1 2096
 erlotinib 1786, 2803
 E-selectin 3014
 ESFT 195
 esophageal cancer 1367
 estradiol 1522
 ethinylestradiol 1537
 ethnicity 780
 ETV1 1625
 European Organisation for Research and Treatment of Cancer QLQ-C30 852
 evaluation 2987
 evening appointment 597
 everolimus 1482, 1755
 evolutionary game theory 1056
 Ewing sarcoma 2696, 658
 ex vivo 1223
 excess treatment costs 2051
 exemestane 2453
 exogenous hormones 1954
 extended therapy 589
 external gamma radiation 1989
 extracellular ATP 1666
 extracellular matrix proteins 3049
 EZN-4176 2579
 fallopian tube cancer 603
 false-positive referral 2044
 family history 788
 female 859
 fertility 615, 2778
 FFPE 2404
 FGFR1 2248
 FGFR3 50
 FHL2 114
 fibrinogen 1123
 filtered coffee 1344
 fine-needle biopsies 2646
 first treatment evaluation 2998
 fish 756
 FKBP51 signalling 2189
 flavonoids 1914
 fluorodeoxyglucose positron emission tomography-computed tomography 1445
 focal adhesion turnover 2810
 folate 2175
 FOLFOX/XELOX 2765
 follicular lymphoma 1287
 follow-up 29, 312, 623, 866, 1766
 food 2904
 four-and-a-half LIM domains protein 2 114
 FOXO3 protein 387
 FOXO3a 1198
 fragile sites 2347
 FSH 1522
 FTO 872
 fucosyltransferase 3014
 fulvestrant resistance 2751
 functional characterisation 2228
 Fyn 1214
 gallbladder cancer 915
 GalNAc-T3 472
 GalNAc-T6 472
 gamma-glutamyltransferase 610
 gamma-glutamyltranspeptidase (GGT) 610
 gastric cancer 379, 2199, 2217, 2619
 gastrointestinal cancer 2829
 gastrointestinal stromal tumour 1403, 2309, 2574
 gefinitib 1786
 gemcitabine 915, 2566
 gemcitabine resistance 502
 gemcitabine-refractory 920
 gene amplification 299
 gene expression 1599, 2228, 2286
 gene fusion 1051
 gene methylation 1775
 genetic 714
 genetic testing 777
 genomics 1636
 GEP-based score 676
 geriatric oncology 272
 germ cell and embryonal 60
 germ cell tumours 2744
 γ -glutamyl hydrolase 2175
 GIST 1403, 1625

- Glasgow Prognostic Score 24
 Gleason grade 2115
 glioblastoma 164, 433, 844, 2853
 GLTSCR2 2199
 glucose-regulated proteins 370
 glycolysis 976
 GNAI1 493
 GNAQ 493
 goserelin 582
 GPER 2751
 graft-vs-tumour effect 2523
 granulosa cell tumour of the ovary 29
 Great Britain 1965
 growth arrest 2587
 growth factors 1056
 GRP78 433
 γ -secretase inhibitor 667
 GSTM3 3105
 guideline adherence 1147
 gynaecological cancer symptoms 882
 gynaecological oncology surgery 623
- H. pylori* eradication 2323
 haematological malignancy 565, 2886
 haemoptysis 1609
 hair colour 747
 Hashimoto's thyroiditis 2496
 HBV infection 2917
 HCC-ART score 1657
 HCV infection 2917
 HDACi 676
 head and neck cancer 172, 1093, 2096, 2629
 head and neck squamous cell carcinoma 482, 1859, 2155, 2973, 3049
 health inequalities 780
 health status disparities 1318
 health-care rationing 888
 health-related quality of life 852
 heat-shock proteins 370
 heat-shock transcription factor-1 1648
 help-seeking 882
 hematopoietic stem cell transplantation 2515
 hepatic resection 1428
 hepatitis 2924
 hepatitis B 573
 hepatitis C virus 2481
 hepatocellular carcinoma 14, 83, 573, 1031, 1198, 1648, 1657, 1904, 2072, 2481, 2654
 HER1/EGFR 2453
 HER2 1157, 2453, 2829, 2453
 hereditary breast cancer 154, 2724
 HES1 1023
 heterogeneity 1056
 HEY1 1023
 Hif1 2131
 Hif1 α 83
 high-grade glioma 844
 histone modifications 299, 994, 3073
 HIV 1974, 1981
 HNSCC 2636
- Hodgkin's lymphoma 280, 2560
 homing 3014
 homologous recombination 3042
 hormonal therapy 1513
 hormone refractory 1711
 hormone replacement therapy 1895, 1954
 hot flashes 1291
 HOTAIR 2266
 HPV 172, 2096
 HPV genotyping 2941
 HPV infection 184
 HPV prevalence 2941
 HPV screening 2941
 HPV types 2941
 HSF1 2654
 hSWI/SNF 2751
 human cytolytic fusion proteins 1570
 human papillomavirus 1766, 1981, 2941
 human tumour xenografts 1562
 HUNT 1310
 hyaluronidase 1556
 hydrophilic 318
 hypersensitivity 1072
 hypertension 2924
 hypothyroidism 215
 hypoxia 50, 1795, 1859, 2597
 hypoxia-regulated miRNAs 50
 hysterectomy 1760
- IAPs 2368
 IFN- β 1198
 IFN- γ 76
 IGF1R/mTOR signalling pathway 2189
 ILK 2842
 image analysis 1618
 imatinib 1403, 1408, 1725, 2309, 2574
 immune cells 1839, 2207
 immune infiltration 1031, 1618
 immune phenotype 76
 immunocytochemistry 1264
 immunocytokines 1206
 immunohistochemistry 1252, 1618, 1839, 1886, 2665, 2833
 immunomagnetic selection 1264
 immunosuppression 280, 1974
 immunotherapy 1570, 2155, 2412
 immunotoxins 1570
 incidence 219, 2467
 indolent ductal carcinoma in situ 2035
 induced gene 100
 inequalities 1181
 inflammation 147, 395, 416, 1839, 2316, 2665
 inflammation-based prognostic system 401
 inflammatory breast cancer 318
 ING4 2842
 inguinofemoral lymphadenectomy 2533
 injury 1504
 insulin resistance 2792
- intensity hypothesis 1965
 interaction 265
 interferon 2481
 interleukin-6 131
 interleukin-2 2412
 internal plutonium exposure 1989
 intra-arterial 2980
 invasion 1137, 1666, 3049
 invasive front 184
 iodine-131 2286
 ionising radiation 2286
 ipilimumab 8
 IRF-1 76
 irinotecan 1420, 1428, 2619, 3067
 Irinotecan sucrosfate 920
 irradiation 1829
 Ishak stage 573
 ITGA6 2636
- Jade Goody 1192
 Jewish 777
 JWA 2842
- Kashmir 1367
 Ki67 1859, 2792
 KIT 559, 1625
 Koehne's risk classification 1428
 KRAS 3057, 3067
 KSR1 2675
- lactate dehydrogenase 2066
 LAMC2 2636
 laryngeal cancer 172
 L-asparaginase 14
 late relapse 2959
 LC-MS/MS 1867
 lead time 2014
 lenvatinib 538
 letrozole 100
 leukaemia 2886
 lifetime drinking 1945
 LINE-1 408
 LINE-1 elements 3073
 lipophilic 318
 liposome 920
 liver cancer 1344, 1997
 liver metastasis 2445
 liver neoplasm 1904
 liver-limited disease 1428
 local inflammatory response 131
 localised prostate cancer 272
 locally advanced 2554
 locoregional recurrence 866
 logistic regression 2880
 long non-coding RNAs 2266
 long-term 545
 long-term survival 1428
 low-dose aspirin 1921
 LPCAT1 1279
 lung adenocarcinoma 1100, 1609
 lung cancer 538, 1467, 1699, 1775, 1954, 2066, 2301, 2404
 lung cancer epidemiology 1974
 lung cancer prognosis 1974
- lung cancer screening 530
 lung neoplasm 2058
 lung progression 1579
 lymph node density 2087
 lymph node metastasis 1685, 1693
 lymph node ratio 1165
 lymphocytes subsets 1676
 lymphoma 1556
 lysine-specific demethylase 1 994
 lysyl oxidase 2237
- magnetic resonance imaging 1528, 2987
 major histocompatibility complex class II 2155
 malignancy 2714
 malignant clone expansion 2819
 malignant melanoma 3116
 malignant mesothelioma 1813
 malnutrition 1093
 mammaglobin B (SCGB2A1) 462
 mammary gland 1829
 mammographic screening 2467
 mammography 597, 2331
 MAPK 493
 markers 714
 Markov model 2035
 Maspin 1636
 matrix degradation 422
 matrix metalloproteinase (MMP) 731
 maxillary sinus 2980
 Mayak radiation workers 1989
 MC1R 747
 MCF-7 breast cancer cells 2751
 MCG 101 1867
 MDM2 2199
 MDR 2356
 MDR1 drug resistance 2131
 mean survival 1735
 meat 756
 meat mutagens 756
 median survival 1735
 Mediterranean diet 1360
 meetings 2295
 MEK 1562
 melanocortin-4 receptor 1867
 melanoma 8, 265, 433, 444, 497, 2412, 2833, 2842
 melatonin 83
 memory T cells 1488
 meningioma 289, 1051
 menopause 1291, 1945
 mesothelioma 552
 mesothelioma latency 1965
 MET 1271, 2248
 meta-analysis 2894
 metabolic response 1157
 metabolic syndrome 60
 metabolism 976
 metastasis 994, 1109, 1137, 1230, 1543, 1636, 1666, 1685, 1829, 2266, 2554, 2636, 2714, 2810, 307, 3092
 metastatic breast cancer 1537
 metastatic colorectal cancer 1428, 3067

- metastatic phenotype 1618
metastatic renal cell carcinoma (mRCC) 2998
metastatic/advanced disease 909
metformin 2792
methionine 1926
methotrexate 2175
methylxanthines 1908
metronomic 1725
metronomic cyclophosphamide 957, 2574
microarray 207, 1394, 1599
microenvironment 1648
microRNA 502, 641, 714, 1243, 1271, 2724, 2744, 2853, 3092
microRNA profiling 2724
microRNAs 452, 2646
microsatellite instability 1004, 3057
migration 207
miR-100 50
miR-106a 452
miR-106b 2323
miR-125b 2853
miR-17 1625
miR-20a 1625
miR-21 2323
miR-221 2714
miR-222 1625, 2714
miR-29s 2636
miR-302c 723
miR-320c 502
miR-34c 1271
miR-375 92
miR-520c 723
miR-591 452
miR-92a 731
miRNA 2189
miRNA 2404, 3116
modelling 2035
moderately emetogenic chemotherapy 859
module validation study 852
molecular diagnosis and prognosis 2404
molecular diagnostic technique 1693
molecular diagnostics 530
monitoring 1528
monocarboxylate transporter-4 1648
mortality 2467
mouse models 658
MRI 2965
MRP-1 195
mTOR 164, 686, 1786
mTOR inhibitors 1755
mTORC1 2389
mTORC2 2389
mucosa-associated lymphoid tissue 1 207
mucositis 2515
multi-disciplinary team 1445, 2295
multidrug resistance 351
multikinase inhibitor 888
multilevel analysis 1437
multiple myeloma 676
multiple treatment lines 2301
multitumour tissue microarray 1848
mutation 1703
mutation analysis 1593
mycosis fungoides 2566
myeloablative conditioning 2523
myeloid leukaemia 1895
nab-paclitaxel 926
nasopharyngeal carcinoma 788, 2462, 2987
National Health Insurance Research Database 2933
natural compounds 2587
neoadjuvant chemotherapy 1157, 1528, 2792, 2798, 2965
neoplasia 1192
neoplasm metastasis 387
neoplasms 60, 1318
nephroureterectomy 1130
Netherlands 2467
nested case-control study 1997
neural stem markers 444
neuroblastoma 433
neuroendocrine tumour 565, 1414
neutrophil-lymphocyte ratio 24, 401, 1755, 1813
next-generation sequencing 827
NF- κ B 76
NGR-hTNF 360
NKG2D ligands 723
nomogram 1109, 1130, 1498, 2774
non-Hodgkin's lymphoma 280, 312
non-invasive imaging 1562
non-melanoma skin cancer 235, 1287
non-persistence 1513
non-small cell lung cancer 530, 545, 1223, 1252, 1264, 1476, 1821, 1974, 2803
Notch 667
notch signalling 1023
NQO1 1325
NRAS 559
nuclear hormone receptor 299
nuclear power 2880
nuclear translocation 76
nulliparity 769
nursing 2121, 3005
nut consumption 2911
nutlin-3 2685, 2954
nutrient 2904
obesity 589, 751, 814
obstructive uropathy 2933
occupational exposure 1965
oesophageal adenocarcinoma 370
oesophageal cancer 1445, 2894
oesophageal squamous cell carcinoma 1109, 2266
oestrogen 100
oestrogen receptor 2453
oncofetal fibronectin 1206
oncogenic mutation 493
ophthalmology 497
oral cancer 207
oral cavity 2087
oral contraceptives 1895, 1954
oral dysplasia 2864
oral health 1367
oral squamous cell carcinoma 1859
oropharyngeal cancer 2904
OSNA 1693
OSSN 1981
osteoporosis/drug therapy 795
osteosarcoma 1579, 2142, 2228, 2607
outreach 1549
ovarian cancer 452, 462, 603, 610, 751, 769, 965, 1072, 1786, 2368, 2744
overall survival 121, 318, 1093, 1760
overdiagnosis 2014
oxaliplatin 1408, 1420, 2396
oxidation 983
p16^{INK4a} 172, 2207
p21 2378
P2Y2 receptor 1666
p38MAPK 2853
p53 2434, 2675, 2685, 2696, 2853, 2954
paclitaxel 92, 538, 1482, 1876
paclitaxel resistance 351, 452
PALB2 154
palliative chemotherapy 1467, 2301
pancreatic cancer 416, 502, 739, 920, 1360, 1795, 1805, 2424, 2911, 2917, 2924
pancreatic intraepithelial neoplasia (PanIN) 2424
parent 836
parity 769
pathological complete response 1157, 2705
pathways 2027
patient experience 780
patient survival 2665
patient-reported 623
patients preferences 633
PAX3/7-FOXO1 3084
pazopanib 1040, 1414
PCNA 2378
PDA 926
pelvic floor 3005
penis cancer 2554
pentraxin family 739
pepsinogen 2323
perimenopausal 582
peritoneum 1685
pERK 915
persin 3034
personalised diagnostics 704
personalised medicine 866
PET-CT 312
P-glycoprotein 351
Pgp 195
pharmacodynamic 897, 1782
pharmacokinetics 1744
pharmacology 2356
phase I clinical trial 897, 1043, 1085, 2560, 2579, 2803
phase II 897
phase III randomised controlled trial 651
phase-1b 1482
phosphoethanolamine 2819
phosphorylated Pyk2 1252
photodynamic therapy 976, 2167
photoreceptor 512
physical activity 761, 814
physical therapy 3005
PI3K 1085
PIAS4 1795
PICT1 2199
pigmentation traits 747
PIK3CA 1085
plasma 3067
plasma DNA 807
platelet-activating factor 1279
platinum-based chemotherapy 1223, 2378, 2548
PLCO 1352
plitidepsin 1451
pN1 1165
Polycomb 299, 1699
polymorphism 957, 1325, 2331 3105
pooled analysis 1954
population-based 272
positron-emission tomography 1414
post-mastectomy radiation therapy 1165
postmenopausal women 761
postoperative complications 623, 1310, 2894
post-treatment surveillance 2973
prediction 3067
prediction of drug sensitivity 676
predictive biomarker 14
predictive biomarkers 1243
predictive factor 1165
premenopausal 582
preoperative chemotherapy 1693
pretargeting 934
pre-therapeutic 1223
PRIMA-1^{Met}/APR-246 2696
primary care trusts 888
primary systemic therapy 2705
Pro187Ser 1325
proanthocyanidins 1914
processing 1394
proctopathy 1504
prognosis 14, 147, 1004, 1013, 1031, 1123, 1137, 1252, 1264, 1338, 1609, 1685, 1782, 1839, 215, 2259, 2266, 2316, 2340, 2445, 2462, 2714, 2778, 2842, 3067, 3105, 395, 416, 472, 573, 610, 788, 2066, 2864
prognostic factors 29, 866, 1165, 1428, 1813, 2714, 3057
prognostic marker 138, 2654
prognostic model 332
prognostic/predictive marker 2765
progression 1460
progression-free survival 318, 1760
proliferation 2189, 2207
propensity score 1904

- prospective cohort study 751, 1344, 1352, 2911
- prostate cancer 641, 651, 747, 950, 957, 983, 1271, 1279, 1666, 1711, 2115, 2121, 2131, 3014, 3023
- prostate cancer treatment 633
- prostate cancer vaccine 1488
- pro-survival signaling 2587
- proteomics 704, 1636, 2142, 2378
- PRRX1 307
- PSA 1488
- PSEN2 2217
- psychological distress 1373
- Pt-(GpG) DNA adducts 1223
- PTEN 1586
- PTEN expression 1703
- public goods 1056
- Pyk2 1252
- pyrosequencing 2833
- QALYs 1172
- Q-TWiST 8
- qualitative 1181
- quality of care 1147
- quality of life 1543, 2301, 2783, 3005
- questionnaire 1543
- race 1945
- radiation 1504, 2340, 3023
- radiation associated breast angiosarcoma 2340
- radical prostatectomy 272
- radical trachelectomy 2778
- radionuclide imaging 934
- radionuclide therapy 934
- radiotherapy 272, 651, 1093, 1117, 2980, 3005
- radon 235
- rapamycin 1586, 2597
- rare tumour 3057
- re-attendance 2044
- rectal cancer 3073
- recurrence 379, 1338, 1460, 1498, 1513, 2973, 3073
- red hair 747
- reduced intensity conditioning 2523
- referral 242, 2027
- registry 1403
- regulatory T cells 2167, 2629
- relapse 29
- relapse risk 2774
- renal cancer 332, 686
- renal cell carcinoma 121, 147, 472, 714, 1123, 1137, 1230, 1750, 1755, 1899, 2389, 3105
- renal cell tumours 2646
- repeated testing 2833
- reporting practices 897
- representative cell line 1599
- research costs 2051
- resection 573
- residents 2507
- resistance 1230, 1593
- response 2798
- response evaluation criteria in solid tumours 1476
- response monitoring 2965
- retina 512
- retinoblastoma 512
- reverse phase protein array (RPPA) 370
- reversine 2810
- Reversion-inducing Cysteine-rich protein with Kazal motifs (RECK) 731
- rhabdomyosarcoma 2523
- ribosomal s6 protein kinase 4 1137
- risk 1914, 3105
- risk assessment 1460
- risk factor 769, 1360, 2904
- risk prediction model 1296
- risk profiles 2115
- risk score 2481
- rituximab 1556
- RMS 3084
- RNAi 3116
- RNA-Seq 1051
- RNAseq 1599
- RO4929097 943
- Ron antibody 482
- Ron receptor 482
- route 2027
- RPL11 2199
- rs1800566 1325
- RTK 3084
- S-1 545, 1420
- S-1 plus cisplatin therapy 2079
- safety 1408
- salivary adenoid cystic carcinoma 444
- sarcoma 1206, 1717
- sarcopenia 325
- SCCC 1981
- schwannoma 289
- screening 35, 249, 603, 1192, 2014
- screening history 35
- screening mammography 2044
- second malignancies 1287
- second-line 920
- SEER program 1318
- self-reporting 2875
- senescence 2207
- sensitivity to apoptosis 1063
- sentinel lymph node biopsy 2533, 2783
- serous carcinoma 603
- SerpinB5 1636
- serum 641
- serum vitamin D 1997
- service provision 1181
- sex cord-stromal tumours 2744
- shear-wave ultrasound 2798
- shiftwork 2472
- shRNA 3116
- sialyl-6-T 2106
- sialyl-Tn 2106
- side population 2619
- sigma-2 receptor 2368
- signal pathways 714
- signal transducer and activator of transcription 3 (STAT3) 731
- signature genes 1599
- SILAC 2675
- sinonasal melanoma 559
- sinusoidal obstruction syndrome 2396
- siRNA 3116
- sirolimus 1786
- skeletal-related events 121
- Smac 2368
- SMAD4 1805
- small intestine adenocarcinoma 3057
- small-cell lung cancer 1482
- SMARCC1 502
- smoking 814, 2489
- Snail 2248
- socioeconomic factors 2489
- soft tissue sarcoma 909, 2316
- sorafenib 342, 888, 915, 2072
- SOX10 444
- SOX9 1023
- spindle cell 2259
- splicing 195
- squamous 2087
- squamous cell carcinoma 1981, 2259
- squamous cell lung cancer subtypes 1599
- Src 1214
- SS18-SSX 1 2279
- SS18-SSX 2 2279
- staging system 2987
- standardized incidence ratios 229
- STAT1 138
- STAT3 83, 138
- statin 249, 318
- stem cells 950, 2587, 3023
- stratification 1886
- stroma 926
- strontium 2886
- STS 1717
- subcutaneous administration 1556
- sunitinib 332, 1040, 1403, 1750, 2309
- supplements 257
- supportive care 888, 2121
- surgery 42, 1109, 2340
- surveillance imaging 312
- surveillance PET 312
- surveys 780
- survival 147, 195, 215, 219, 257, 493, 565, 788, 814, 1302, 1338, 1476, 1676, 1703, 1805, 2005, 2027, 2058, 2066, 2087, 2462, 2548, 2735, 2894, 2973, 3073
- survival after surgery 401
- survival analysis 29, 2279
- survivorship 1373, 2121
- symptom survey 882
- synergistic antitumour 342
- synergy 2005
- synovial sarcoma 2279
- systemic analysis 704
- systemic inflammatory response 131, 401
- Taiwan 2933
- tamoxifen 582, 1172, 2453, 3034
- targeted therapy 332, 909, 1755, 2142, 2607
- taxane 2131
- T-cell lymphoma 280
- tea 1352, 1908
- telomerase 497
- temsirolimus 1711, 2389
- tenovin-6 2434
- testicular 2744
- testicular cancer 891
- testicular tumours 68
- testosterone 950
- tetrandrine 342, 2864
- TFII-I 3042
- TGF β 2167
- therapeutic target 1579
- therapy 2714
- thoracic surgery 2058
- thrombocytosis 401
- thyroid cancer 2286
- thyroid gland 215
- thyroid-stimulating hormone 215
- tissue microarray 138, 387
- tivantinib 2803
- TKI 1040
- TNF signalling 422
- TNF- α 76
- TNFAIP8 1685
- toluidine sulphamide 2131
- tooth loss 1367
- torisel 1711
- TP53 1214, 2199
- trabectedin 1717
- trachelectomy 615
- TRAIL 2685
- training 2507
- transcription factor 3042
- transforming growth factor- β 207
- transplantation 280
- trastuzumab 1556
- treatment cost savings 2051
- treatment costs 2051
- treatment sequencing 1079
- trends 242, 1318
- triadic consultation 2507
- trials 1
- triple-negative breast cancer 2347
- truncation mutation 299
- TSU-68 2079
- tubal ligation 1291
- tuberculosis infections 229
- tuberculosis 2933
- tumorigenicity 2228
- tumour angiogenesis 2237
- tumour antigens 2155
- tumour differentiation 2424
- tumour dimensions 1476
- tumour endothelial cells 2237
- tumour glycosylation 2106

- tumour invasion 422
tumour microenvironment 2412
tumour morphology 154
tumour necrosis 131
tumour progression 3049
tumour response 1528, 2356
tumour shrinkage 2998
tumour size 1476, 2035
tumour suppressor 2636
tumour suppressor gene 807
tumour targeting 360
tumour-associated antigen 1031
tumourigenesis 3092
tumour-infiltrating lymphocyte 1013, 2629, 2705
tumour-infiltrating macrophage 1013
tumour-necrosis factor 1206
tumour-stage characteristics 1921
- two-dimensional electrophoresis 1867
tyrosine kinase inhibitor 538, 686, 1230, 1403, 1593, 1755, 1821
UGT 950
UK 2875
UKGOSOC 623
ulcerative colitis 694
unknown primary 1318
uPAR 2714
upper urinary tract 1130
urinary irritative symptoms 3005
urinary tract cancer 2933
urokinase-type plasminogen activator system 2714
urologists 633
urothelial carcinoma 1130, 2548
- uterine cervical neoplasms 2489
uveal melanoma 493
- validation 1123, 1130, 1296, 1460, 1498, 2774
vascular invasion 472, 1609
vascular targeting 360, 1206
VEGF 83, 957
VEGF-targeted therapy 2998
VELOUR 1735
vinflunine 2548
vinorelbine 1467
viral oncogenesis 172
vitamin B₁₂ 1926
vitamin B₆ 1926
vitamin C 257
vitamin D 747
vulva 2259
- vulvar cancer 184, 2533
VX-680 2607
- waiting times 42
weekend appointments 597
weight gain 872, 1310
weight loss 1093
whole-body magnetic resonance imaging 658
whole-genome microarray 2286
Wnt 667
wortmannin 1586
- XPF 2096
- young women 35, 109, 1302
- ZD6474 164
ZM447439 2607
ZSTK474 1786